Top

Neuroradiology

Published in:

01-01-2015 | Diagnostic Neuroradiology

Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI

Authors: Stephanie Lescher, Alina Jurcoane, Andreas Veit, Oliver Bähr, Ralf Deichmann, Elke Hattingen

Published in: Neuroradiology | Issue 1/2015

Abstract

Introduction

Treatment with the humanized anti-vascular endothelial growth factor (VEGF) antibody bevacizumab in glioblastoma patients suppresses contrast enhancement via the reduction of vascular permeability, which does not necessarily indicate real reduction of tumor cell mass. Therefore, other imaging criteria are needed to recognize tumor growth under bevacizumab more reliably. It is still unknown, whether quantitative T1 mapping is useful to monitor the effects of anti-angiogenic therapy or to indicate a tumor progression earlier and more reliable compared to conventional magnetic resonance imaging (MRI) sequences. This raised the question whether quantitative T1 mapping is more suitable to monitor treatment effects of bevacizumab.

Methods

Conventional and quantitative MRI was performed on six consecutive patients with recurrent glioblastoma before treatment with bevacizumab and every 8 weeks thereafter until further tumor progression. Quantitative T1 maps before and after intravenous application of contrast agent and quantitative T2 maps were performed to calculate serial differential maps and subtraction maps from one time point, subtracting contrast-enhanced T1 maps from non-contrast T1 maps.

Results

In five illustrative cases, tumor progression was documented earlier in differential T1 relaxation time (DiffT1) and T2 relaxation time (DiffT2) maps before changes in the conventional MRI studies were obvious. Four patients showed previous prolongation of T1 relaxation time in the DiffT1 maps, suggesting tumor progression, and subtraction maps revealed faint contrast enhancement matching with the areas of T1 prolongation.

Conclusion

Our results emphasize that quantitative relaxation time mapping could be a promising method for tumor monitoring in glioblastoma patients under anti-angiogenic therapy. Quantitative T1 mapping seems to detect enhancing tumor earlier than conventional contrast-enhanced T1-weighted images.

Available only for authorised users

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996PubMedCrossRef

Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572–2578PubMed

Saitta L, Heese O, Förster AF et al (2011) Signal intensity in T2′ magnetic resonance imaging is related to brain glioma grade. Eur Radiol 21(5):1068–1076PubMedCrossRef

Wick W, Puduvalli VK, Chamberlain MC et al (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28(7):1168–1174PubMedCentralPubMedCrossRef

Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729PubMedCrossRef

Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740PubMedCrossRef

Stark-Vance V (2005) Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract]. Proceedings of the World Federation of Neuro-Oncology Meeting. Neuro-Oncol 7:369

Wagner SA, Desjardins A, Reardon DA et al (2008) Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas [abstract]. J Clin Oncol 26:2021CrossRef

Claes A, Gambarota G, Hamans B et al (2008) Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment. Int J Cancer 22:1981–1986

10.

Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787PubMedCrossRef

11.

Macdonald D, Cascino T, Schold SJ et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280PubMed

12.

Casanovas O, Hicklin DJ, Bergers G et al (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8(4):299–309PubMedCrossRef

13.

da Cruz LC H Jr, Rodriguez I, Domingues RC et al (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. Am J Neuroradiol 32(11):1978–1985CrossRef

14.

Brandsma D, van den Bent MJ (2009) Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22(6):633–638, ReviewPubMedCrossRef

15.

Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972PubMedCrossRef

16.

Pope WB, Hessel C (2011) Response assessment in neuro-oncology criteria: implementation challenges in multicenter neuro-oncology trials. AJNR Am J Neuroradiol 32(5):794–797PubMedCrossRef

17.

Hattingen E, Jurcoane A, Daneshvar K et al (2013) Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival. Neurooncol 15(10):1395–404

18.

Rieger J, Bähr O, Muller K et al (2010) Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. Neurooncol 99(1):49–56CrossRef

19.

Araki T, Inouye T, Suzuki H et al (1984) Magnetic resonance imaging of brain tumors: measurement of T1. Work in progress. Radiol 150(1):95–98CrossRef

20.

Englund E, Brun A, Larsson EM et al (1986) Tumours of the central nervous system. Proton magnetic resonance relaxation times T1 and T2 and histopathologic correlates. Acta Radiol Diagn 27:653–659

21.

Le Bas JF, Leviel JL, Decorps M et al (1984) NMR relaxation times from serial stereotactic biopsies in human brain tumors. J Comput Assist Tomogr 8:1048–1057PubMedCrossRef

22.

Ellingson BM, Kim HJ, Woodworth DC et al (2014) Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 271(1):200–210PubMedCrossRef

23.

Preibisch C, Deichmann R (2009) T-1 mapping using spoiled FLASH-EPI hybrid sequences and varying flip angles. Magn Reson Imaging 62:240–246

24.

Howarth C, Hutton C, Deichmann R (2006) Improvement of the image quality of T1-weighted anatomical brain scans. Neuroimaging 29:930–937CrossRef

25.

Venkatesan R, Lin WL, Haacke EM (1998) Accurate determination of spin-density and T-1 in the presence of RF-field inhomogeneities and flip-angle miscalibration. Magn Reson Med 40:592–602PubMedCrossRef

26.

Volz S, Noth U, Rotarska-Jagiela A et al (2010) A fast B1-mapping method for the correction and normalization of magnetization transfer ratio maps at 3T. Neuroimaging 49:3015–3026CrossRef

27.

Hattingen E, Jurcoane A, Bähr O et al (2011) Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. Neurooncol 13(12):1349–1363

28.

Ellingson BM, Cloughesy TF, Lai A et al (2012) Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J Neurooncol 106(1):111–119PubMedCrossRef

29.

Jenkinson M, Beckmann CF, Behrens TE et al (2012) FSL Neuroimaging 62(2):782–790CrossRef

30.

Jurcoane A, Wagner M, Schmidt C et al (2013) Within-lesion differences in quantitative MRI parameters predict contrast enhancement in multiple sclerosis. J Magn Reson Imaging 38(6):1454–1561PubMedCrossRef

31.

Mottershead JP, Schmierer K, Clemence M et al (2003) High field MRI correlates of myelin content and axonal density in multiple sclerosis—a post-mortem study of the spinal cord. J Neurol 250:1293–1301PubMedCrossRef

32.

Seewann A, Vrenken H, van der Valk P et al (2009) Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis. Arch Neurol 66:601–609PubMed

33.

van Waesberghe JH, Kamphorst W, De Groot CJ et al (1999) Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 46:747–754PubMedCrossRef

34.

Chiba Y, Sasayama T, Miyake S et al (2008) Anti-VEGF receptor antagonist (VGA1155) reduces infarction in rat permanent focal brain ischemia. Kobe J Med Sci 54(2):136–146

35.

Deoni SC, Peters TM, Rutt BK (2004) Determination of optimal angles for variable nutation proton magnetic spin-lattice, T1, and spin-spin, T2, relaxation times measurement. Magn Reson Med 51:194–199PubMedCrossRef

36.

Deichmann R (2006) Fast structural brain imaging using an MDEFT sequence with a FLASH-EPI hybrid readout. Neuroimaging 33:1066–1071CrossRef

37.

Katz D, Taubenberger JK, Cannella B et al (1993) Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 34:661–669PubMedCrossRef

38.

Brück W, Bitsch A, Kolenda H et al (1997) Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 42:783–793PubMedCrossRef

39.

Oh J, Cha S, Aiken AH et al (2005) Quantitative apparent diffusion coefficients and T2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema. J Magn Reson Imaging 21(6):701–708PubMedCrossRef

40.

Hoehn-Berlage M, Tolxdorff T, Bockhorst K et al (1992) In vivo NMRT2 relaxation of experimental brain tumors in the cat: a multiparameter tissue characterization. Magn Reson Imaging 10(6):935–947PubMedCrossRef

41.

Eis M, Els T, Hoehn-Berlage M (1995) High resolution quantitative relaxation and diffusion MRI of three different experimental brain tumors in rat. Magn Reson Med 34(6):835–844PubMedCrossRef

Title: Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI
Authors: Stephanie Lescher
Alina Jurcoane
Andreas Veit
Oliver Bähr
Ralf Deichmann
Elke Hattingen
Publication date: 01-01-2015
Publisher: Springer Berlin Heidelberg
Published in: Neuroradiology / Issue 1/2015
Print ISSN: 0028-3940
Electronic ISSN: 1432-1920
DOI: https://doi.org/10.1007/s00234-014-1445-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

XLIII ANNUAL MEETING OF SPANISH SOCIETY OF NEURORADIOGY

Suspected cerebral foreign body granuloma following endovascular treatment of intracranial aneurysm: imaging features

Observer reliability of CT angiography in the assessment of acute ischaemic stroke: data from the Third International Stroke Trial

European Society of Neuroradiology (ESNR)

CNS imaging findings associated with Parry–Romberg syndrome and en coup de sabre: correlation to dermatologic and neurologic abnormalities

Childhood encephalitis: relationship between diffusion abnormalities and clinical outcome